Shots:

• The P-II (KEYNOTE-695) trial evaluating TAVO-EP (intratumoral) + pembrolizumab (IV) in 152 patients with unresectable or metastatic (stage III/IV) melanoma who had progressed on immediate prior anti-PD-1 Ab therapy
• The trial met its 2EPs i.e., the therapy showed an ORR of 18.8% among 101 efficacy evaluable patients with one post-baseline tumor assessment & exceeds the pre-specified ORR of ≥17%, 3 patients achieved a CR and 16 PR; DCR (40.6%), durable response rate (15.8%) @≥24wks.; m-DoR (not reached); m-OS (22.7mos.) after a median follow-up period of 33.4mos. The combination therapy was well tolerated with no grade 4/5 TRAEs. & grade 3 TRAEs (4.8%)
• Additionally, nivolumab/ipilimumab treatment had been stopped in 2 patients with CR. The results from the 1EPs are expected in Q1’23

Ref: OncoSec  | Image: OncoSec